Catch the replay of Sona Nanotech’s March 18th investor webinar.
Hear from David Regan (CEO), Dr. Carman Giacomantonio (CMO), and Dr. Carlos Rojas Principal Investigator from Bradford Hill as they discuss follow-up data from Sona’s first-in-human Targeted Hyperthermia Therapy (THT) melanoma study.
The session covers clinical outcomes, including immune responses observed in treated tumors and continued evaluation of patient follow-up data.